Table 1 Treatment initiation and continuation regimens of Phase 3 randomized controlled trial of anti-VEGF in DME

RIDE/RISE

NCT00473382

NCT00473330

Fixed q4 intervals ranibizumab

 (no reduction before week 156 in the open-label extension) [4]

Week 88/week 92

RESTORE

NCT00687804

Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [5, 6]

Week 40

RELIGHT

NCT01257815

Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [7]

Week 24

REVEAL

NCT00989989

Initial 3 q4 intervals followed by PRN (protocol-driven) ranibizumab retreatment [8]

Week 32

DRCR protocol I

NCT00445003

Initial 4 q4 intervals ranibizumab followed by protocol-driven ranibizumab retreatment [9]

Week 232

DRCR.net protocol T

NCT01627249

Aggressive retreatment protocol for IAI, bevacizumab, and ranibizumab prior to 24-week visit with q4 intervals [10]

Week 32, week 52

VIVID/VISTA

NCT01363440 NCT01331681

Initial 5 q4 intervals IAI followed by 2q8 or 2q4 intervals [11]

Week 44

BOLT

EUDRACT2007-000847-89

Initial 3 q6 intervals bevacizumab (initially combined with laser) followed by PRN (protocol-driven) bevacizumab retreatment [12]

Week 100